Accéder au contenu
Merck

Hematogenous macrophage depletion reduces the fibrotic scar and increases axonal growth after spinal cord injury.

Neurobiology of disease (2014-12-03)
Y Zhu, C Soderblom, V Krishnan, J Ashbaugh, J R Bethea, J K Lee
RÉSUMÉ

Spinal cord injury (SCI) leads to formation of a fibrotic scar that is inhibitory to axon regeneration. Recent evidence indicates that the fibrotic scar is formed by perivascular fibroblasts, but the mechanism by which they are recruited to the injury site is unknown. Using bone marrow transplantation in mouse model of spinal cord injury, we show that fibroblasts in the fibrotic scar are associated with hematogenous macrophages rather than microglia, which are limited to the surrounding astroglial scar. Depletion of hematogenous macrophages results in reduced fibroblast density and basal lamina formation that is associated with increased axonal growth in the fibrotic scar. Cytokine gene expression analysis after macrophage depletion indicates that decreased Tnfsf8, Tnfsf13 (tumor necrosis factor superfamily members) and increased BMP1-7 (bone morphogenetic proteins) expression may serve as anti-fibrotic mechanisms. Our study demonstrates that hematogenous macrophages are necessary for fibrotic scar formation and macrophage depletion results in changes in multiple cytokines that make the injury site less fibrotic and more conducive to axonal growth.

MATÉRIAUX
Numéro du produit
Marque
Description du produit

Sigma-Aldrich
Diméthylsulfoxyde, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Tétrahydrofurane, inhibitor-free, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Diméthylsulfoxyde, ACS reagent, ≥99.9%
Sigma-Aldrich
Diméthylsulfoxyde, Molecular Biology
Sigma-Aldrich
Diméthylsulfoxyde, suitable for HPLC, ≥99.7%
Sigma-Aldrich
Diméthylsulfoxyde, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
Diméthylsulfoxyde, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Tétrahydrofurane, contains 200-400 ppm BHT as inhibitor, ACS reagent, ≥99.0%
Sigma-Aldrich
Diméthylsulfoxyde, anhydrous, ≥99.9%
Sigma-Aldrich
Tétrahydrofurane, anhydrous, ≥99.9%, inhibitor-free
Sigma-Aldrich
Tétrahydrofurane, anhydrous, contains 250 ppm BHT as inhibitor, ≥99.9%
Sigma-Aldrich
Diméthylsulfoxyde, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Alcool benzylique, ReagentPlus®, ≥99%
Sigma-Aldrich
Alcool benzylique, ACS reagent, ≥99.0%
Supelco
Alcool benzylique, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Anti-laminine antibody produced in rabbit, 0.5 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Diméthylsulfoxyde, BioUltra, Molecular Biology, ≥99.5% (GC)
USP
Alcool benzylique, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Diméthylsulfoxyde, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
Alcool benzylique, anhydrous, 99.8%
Sigma-Aldrich
Tétrahydrofurane, ACS reagent, ≥99.0%, contains 200-400 ppm BHT as inhibitor
Sigma-Aldrich
Diméthylsulfoxyde, PCR Reagent
Sigma-Aldrich
Alcool benzylique, puriss. p.a., ACS reagent, ≥99.0% (GC)
Sigma-Aldrich
Benzyl benzoate, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Alcool benzylique, ≥99%, FCC, FG
Supelco
Alcool benzylique, analytical standard
Sigma-Aldrich
Benzyl benzoate, ≥99%, FCC, FG
Sigma-Aldrich
Xylazine, ≥99%
Supelco
Tétrahydrofurane, analytical standard